Ensuring the Continuous Supply of Quality Drug Products During Uncertain Times

Sponsored Content

The global coronavirus pandemic has tested the abilities of bio/pharmaceutical companies to develop new therapies and maintain-or even accelerate-production of existing drugs. In this webcast, experts will discuss business continuity practices, regulatory compliance, and supply chain management under current-or future-emergency conditions. Live: Tuesday, Apr. 28, 2020 at 11 am EDT | 10 am CDT | 8 am PDT On Demand: available after airing until Apr. 28, 2021 Register free

Register free: http://www.pharmtech.com/pt_w/business_continuity_practices

Event Overview:

The global coronavirus pandemic has tested the abilities of bio/pharmaceutical companies to develop new therapies and maintain-or even accelerate-production of existing drugs. Travel bans, restricted access to facilities, and supply chain disruptions are just a few of the challenges facing drug companies, that must provide essential medicines under adverse conditions while protecting their employees and adhering to good manufacturing practices.

In the initial weeks of the coronavirus pandemic, bio/pharma companies, contract service providers, and regulatory authorities have taken measures to ensure continued operations during the present emergency. While addressing the challenges of today, the bio/pharma industry also needs to look ahead to what may be new operating conditions for the coming months or years.

Join the editors of Pharmaceutical Technology and BioPharm International for interviews and discussions with experts about business continuity practices, regulatory compliance, and supply chain management under current-or future-emergency conditions.

Key Learning Objectives:

  • Business continuity best practices

  • Employee and facility safety

  • Regulatory compliance

  • Addressing deviations

  • Testing guidance for new and existing drugs

  • Supplier oversight

  • Supply chain challenges

  • Data security, data integrity, and remote data access and collaboration

Speakers: Mary Blenn, vice-president, global supply chain, Cytiva

Lisia Marina Scholz Dias, lead application engineer, Applied Materials

Steve Goldman, head of Steve Goldman Associates, a risk management and business continuity consultancy

David Light, CEO of Valisure

Ron Najafi, CEO of Emery Pharma

Susan Schniepp, a distinguished fellow for Regulatory Compliance Associates

Angelo Stracquatanio, CEO, apprentice.io

 

Japp Venema, CSO, USP 

Time and Date: Tuesday, Apr. 28, 2020 at 11 am EDT | 10 am CDT | 8 am PDT

On demand available after airing until Apr. 28, 2021.

Sponsors: Honeywell, AbbVie, Applied Materials

Register free: http://www.pharmtech.com/pt_w/business_continuity_practices